NPCE News & Events

NeuroPace announced FDA approval of ECoG Assistant. This milestone represents an important step in NeuroPace's broader AI platform strategy. "This approval underscores how NeuroPace's data advantage is translating into practical tools for clinicians today," said Joel Becker, Chief Executive Officer of NeuroPace. "AI-driven insights offer the unique potential to improve the efficiency of epilepsy care now while building a platform that can unlock new opportunities over time to further personalize therapy and improve outcomes."

Consensus $98.9M. Reiterates FY26 gross margin between 81.5% and 82.5% and increases Adjusted EBITDA to ($8.5M) and ($9.5M) compared to previous guidance between ($9.0M) to ($10.0M).

Reports Q1 revenue $22.1M, consensus $21.7M. "First quarter results reflect continued execution against the strategic priorities we outlined earlier this year," said Joel Becker, Chief Executive Officer of NeuroPace. "We remain focused on driving disciplined growth in our core RNS business, advancing our product roadmap, and progressing toward potential indication expansion, all while strengthening the operational foundation of the Company. We continue to progress NAUTILUS through the regulatory review process and remain encouraged by the totality of the dataset supporting the IGE indication expansion."